NASDAQ:QTRX Quanterix - QTRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Quanterix Co. Please log in to your account or sign up in order to add this asset to your watchlist. $14.82 +0.47 (+3.28%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$14.34▼$15.3550-Day Range$11.75▼$14.8252-Week Range$6.31▼$35.98Volume633,038 shsAverage Volume331,093 shsMarket Capitalization$549.23 millionP/E RatioN/ADividend YieldN/APrice Target$26.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Quanterix MarketRank™ ForecastAnalyst RatingHold2.14 Rating ScoreUpside/Downside75.4% Upside$26.00 Price TargetShort InterestHealthy2.66% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.09) to ($1.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.97 out of 5 starsMedical Sector653rd out of 1,030 stocksAnalytical Instruments Industry15th out of 27 stocks 3.1 Analyst's Opinion Consensus RatingQuanterix has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.00, Quanterix has a forecasted upside of 75.4% from its current price of $14.82.Amount of Analyst CoverageQuanterix has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.66% of the float of Quanterix has been sold short.Short Interest Ratio / Days to CoverQuanterix has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Quanterix has recently increased by 7.12%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldQuanterix does not currently pay a dividend.Dividend GrowthQuanterix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QTRX. Previous Next 2.6 News and Social Media Coverage News SentimentQuanterix has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.Search Interest2 people have searched for QTRX on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Quanterix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.20% of the stock of Quanterix is held by insiders.Percentage Held by Institutions80.60% of the stock of Quanterix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Quanterix are expected to grow in the coming year, from ($2.09) to ($1.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Quanterix is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Quanterix is -5.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQuanterix has a P/B Ratio of 1.23. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Quanterix (NASDAQ:QTRX) StockQuanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. Its products and services include Simoa Assay Kits, HD-X analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, 2470 Arrayer, Simoa Accelerator Laboratory, Uman NF-Light, and Homebrew -Custom Assay Development. The company was founded by Nicholas J. Naclerio and David R. Walt in April 2007 and is headquartered in Billerica, MA.Read More Receive QTRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quanterix and its competitors with MarketBeat's FREE daily newsletter. Email Address QTRX Stock News HeadlinesJanuary 20, 2023 | finance.yahoo.comBullish Quanterix Corporation (NASDAQ:QTRX) insiders filled their treasuries with US$5.6m worth of stock over last yearJanuary 9, 2023 | finance.yahoo.comQuanterix Announces Appointment of Brian Blaser to Board of DirectorsFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 3, 2023 | finance.yahoo.comQuanterix to Present at 41st Annual J.P. Morgan Healthcare ConferenceDecember 31, 2022 | finance.yahoo.comQuanterix Corporation (QTRX) Stock Historical Prices & Data - Yahoo FinanceDecember 5, 2022 | finance.yahoo.comQuanterix’s Simoa® Technology Drives Advances in Alzheimer’s Disease Research Presented at 2022 Clinical Trials on Alzheimer’s Disease (CTAD) ConferenceNovember 16, 2022 | finance.yahoo.comQuanterix to Participate in the 15th Clinical Trials on Alzheimer’s Disease (CTAD) Task ForceNovember 10, 2022 | finance.yahoo.comQuanterix to Participate in the Canaccord MedTech, Diagnostics and Digital Health & Services ForumFebruary 3, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.November 10, 2022 | finance.yahoo.comQuanterix Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS LagsNovember 8, 2022 | finance.yahoo.comQuanterix Corporation (QTRX) Reports Q3 Loss, Tops Revenue EstimatesNovember 8, 2022 | finance.yahoo.comQuanterix Corporation Releases Operating Results for Third Quarter 2022November 1, 2022 | finance.yahoo.comQuanterix’ Third Quarter 2022 Earnings Conference CallOctober 15, 2022 | businesswire.comCASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Cassava Sciences, Inc. - SAVA - Business WireOctober 14, 2022 | benzinga.comCASSAVA SCIENCES INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Con - BenzingaOctober 12, 2022 | nasdaq.comQuanterix (NASDAQ:QTRX) dips 20% this week as increasing losses might not be inspiring confidence among its investors - NasdaqSeptember 29, 2022 | finance.yahoo.comGlobal Neurological Biomarkers Market is Expected to Reach $18.9 Billion by 2031: Says AMR - Yahoo FinanceSeptember 28, 2022 | seekingalpha.comProthena, bioAffinity top healthcare gainers; Mind Medicine, Gamida lead losers' pack - Seeking AlphaSeptember 28, 2022 | seekingalpha.comQuanterix Corporation: Selling For Less Than Cash ValueSeptember 28, 2022 | benzinga.comWhy MindMed Is Trading Lower By Around 35%; Here Are 31 Stocks Moving Premarket - AIM ImmunoTech (AMEX:AI - BenzingaSeptember 24, 2022 | thestreet.comQuanterix Uses JPMorgan Healthcare Conference to Scout Sales CandidatesSeptember 24, 2022 | ca.finance.yahoo.comQuanterix Corporation (QTRX)September 8, 2022 | nasdaq.comWall Street Analysts Predict a 73% Upside in Quanterix Corporation (QTRX): Here's What You Should Know - NasdaqSeptember 7, 2022 | finance.yahoo.comWall Street Analysts Predict a 73% Upside in Quanterix Corporation (QTRX): Here's What You Should KnowAugust 31, 2022 | benzinga.com(QTRX) – Quanterix's Return On Capital Employed Overview - BenzingaAugust 31, 2022 | msn.comQuanterix's Return On Capital Employed OverviewAugust 18, 2022 | seekingalpha.comQuanterix stock pops after insider buys reported by CEO and CFO (NASDAQ:QTRX) - Seeking AlphaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive QTRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Quanterix and its competitors with MarketBeat's FREE daily newsletter. Email Address QTRX Company Calendar Last Earnings11/08/2022Today2/02/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:QTRX CUSIPN/A CIK1503274 Webwww.quanterix.com Phone(617) 301-9400FaxN/AEmployees460Year FoundedN/APrice Target and Rating Average Stock Price Forecast$26.00 High Stock Price Forecast$60.00 Low Stock Price Forecast$12.00 Forecasted Upside/Downside+75.4%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,690,000.00 Net Margins-89.24% Pretax Margin-89.29% Return on Equity-18.91% Return on Assets-16.03% Debt Debt-to-Equity RatioN/A Current Ratio13.54 Quick Ratio12.90 Sales & Book Value Annual Sales$110.56 million Price / Sales4.97 Cash FlowN/A Price / Cash FlowN/A Book Value$12.03 per share Price / Book1.23Miscellaneous Outstanding Shares37,060,000Free Float34,016,000Market Cap$549.23 million OptionableNot Optionable Beta1.32 Key ExecutivesMasoud TolouePresident, Chief Executive Officer & DirectorDaniel PikoraChief Operating OfficerMichael A. DoyleChief Financial OfficerDavid C. DuffyChief Technology Officer & Vice President-ResearchRichard HaighSenior Vice President-Research ProductsKey CompetitorsBionano GenomicsNASDAQ:BNGOAkoya BiosciencesNASDAQ:AKYACue HealthNASDAQ:HLTHSeerNASDAQ:SEERNautilus BiotechnologyNASDAQ:NAUTView All CompetitorsInsiders & InstitutionsSimplex Trading LLCBought 21,300 shares on 2/2/2023Ownership: 0.000%Nisa Investment Advisors LLCBought 795 shares on 2/2/2023Ownership: 0.007%CWM LLCSold 31,799 shares on 2/1/2023Ownership: 0.449%Zurcher Kantonalbank Zurich Cantonalbank Bought 1,423 shares on 2/1/2023Ownership: 0.013%New York State Common Retirement FundSold 972 shares on 1/30/2023Ownership: 0.160%View All Insider TransactionsView All Institutional Transactions QTRX Stock - Frequently Asked Questions Should I buy or sell Quanterix stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" QTRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QTRX, but not buy additional shares or sell existing shares. View QTRX analyst ratings or view top-rated stocks. What is Quanterix's stock price forecast for 2023? 7 analysts have issued 12-month price objectives for Quanterix's stock. Their QTRX share price forecasts range from $12.00 to $60.00. On average, they expect the company's stock price to reach $26.00 in the next year. This suggests a possible upside of 75.4% from the stock's current price. View analysts price targets for QTRX or view top-rated stocks among Wall Street analysts. How have QTRX shares performed in 2023? Quanterix's stock was trading at $13.85 at the beginning of the year. Since then, QTRX stock has increased by 7.0% and is now trading at $14.82. View the best growth stocks for 2023 here. When is Quanterix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our QTRX earnings forecast. How were Quanterix's earnings last quarter? Quanterix Co. (NASDAQ:QTRX) released its earnings results on Tuesday, November, 8th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.02. The firm had revenue of $26.65 million for the quarter, compared to analyst estimates of $22.56 million. Quanterix had a negative trailing twelve-month return on equity of 18.91% and a negative net margin of 89.24%. What is Kevin Hrusovsky's approval rating as Quanterix's CEO? 15 employees have rated Quanterix Chief Executive Officer Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among the company's employees. What other stocks do shareholders of Quanterix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT), Novavax (NVAX), Akoustis Technologies (AKTS), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Walt Disney (DIS), Illumina (ILMN), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and Intellia Therapeutics (NTLA). When did Quanterix IPO? (QTRX) raised $50 million in an initial public offering (IPO) on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners acted as the underwriters for the IPO and BTIG and Evercore ISI were co-managers. What is Quanterix's stock symbol? Quanterix trades on the NASDAQ under the ticker symbol "QTRX." Who are Quanterix's major shareholders? Quanterix's stock is owned by many different institutional and retail investors. Top institutional shareholders include CWM LLC (0.45%), New York State Common Retirement Fund (0.16%), Strs Ohio (0.12%), Simplex Trading LLC (0.00%), Dupont Capital Management Corp (0.05%) and Versor Investments LP (0.05%). Insiders that own company stock include Amol Chaubal, David C Duffy, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, John J Fry, Marijn E Dekkers, Marijn E Dekkers, Mark T Roskey, Mark T Roskey, Martin D Madaus, Masoud Toloue and Michael A Doyle. View institutional ownership trends. How do I buy shares of Quanterix? Shares of QTRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Quanterix's stock price today? One share of QTRX stock can currently be purchased for approximately $14.82. How much money does Quanterix make? Quanterix (NASDAQ:QTRX) has a market capitalization of $549.23 million and generates $110.56 million in revenue each year. The company earns $-57,690,000.00 in net income (profit) each year or ($2.66) on an earnings per share basis. How many employees does Quanterix have? The company employs 460 workers across the globe. How can I contact Quanterix? Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The official website for the company is www.quanterix.com. The company can be reached via phone at (617) 301-9400 or via email at ir@quanterix.com. This page (NASDAQ:QTRX) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.